TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32460879
Drug: Ondansetron oral
Normalized name: Ondansetron Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron oral solution (six doses over 48 hours)
Study: 32460879
Drug: Placebo (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (six doses over 48 hours)
Study: 35695006
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Revacept
Study: 35695006
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Revacept
Study: 35075525
Drug: Structured behavioral
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured behavioral support program with 7-weekly sessions
Study: 32078469
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg twice a day for 3 days)
Study: 32926507
Drug: pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 200 mg every 3 weeks (35 cycles)
Study: 32926507
Drug: chemotherapy (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (four to six cycles)
Study: 35130196
Drug: Dual injection
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual injection
Study: 34533816
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (MT) with taping
Study: 34533816
Drug: Modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint‐induced movement therapy (mCIMT) alone
Study: 34533816
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (MT) alone
Study: 34098301
Drug: MOUD (Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOUD (Medication for Opioid Use Disorder)
Study: 34098301
Drug: XR-NTX (Extended-Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX (Extended-Release Naltrexone)
Study: 34602484
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamin therapy (daily folic acid 0.8 mg, vitamin B12 0.5 mg, vitamin B6 20 mg)
Study: 32290829
Drug: Oral dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextrose
Study: 36193322
Drug: Fu's subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu's subcutaneous needling therapy (FSN), treated once every other day for 5 consecutive treatments.
Study: 36193322
Drug: Acupuncture, treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, treated once a day for 10 consecutive treatments.
Study: 32469835
Drug: Modified group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified group cognitive behavioral therapy (CBT), 8 weekly sessions of 60 minutes each
Study: 35856326
Drug: Vapocoolant (cold)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant (cold) spray
Study: 35856326
Drug: Injection without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection without anesthesia
Study: 33570228
Drug: Phyllanthus emblica
Normalized name: PHYLLANTHUS EMBLICA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus emblica capsule (500 mg) twice daily for 12 weeks
Study: 33570228
Drug: Phyllanthus emblica
Normalized name: PHYLLANTHUS EMBLICA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus emblica capsule (500 mg)
Study: 33494637
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) including intra-arterial thrombolysis and mechanical thrombectomy (MT; ±IVT)
Study: 33494637
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) after 2015
Study: 34032043
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml compound betamethasone injection
Study: 34032043
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml hyaluronic acid and 1 ml compound betamethasone injection
Study: 34999335
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid, carotenoid and vitamin E supplementation (1 g fish oil, 430 mg DHA, 90 mg EPA, 22 mg carotenoids, 15 mg vitamin E)
Study: 33388700
Drug: Treatment-as-usual plus
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual plus aerobic walking (TAW)
Study: 35019055
Drug: Mindfulness-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based treatment (MBT)
Study: 35723758
Drug: Pemetrexed +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed + treatment
Study: 35723758
Drug: Pemetrexed -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed - treatment
Study: 35723758
Drug: Pemetrexed +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed + treatment (among patients with at least four lines of prior treatment)
Study: 35723758
Drug: Pemetrexed -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed - treatment (among patients with at least four lines of prior treatment)
Study: 34601077
Drug: Hydrogen-rich water
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich water (HRW) 0.5 L per day (15 ppm of hydrogen)
Study: 32886901
Drug: Upfront lanreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront lanreotide (120 mg)
Study: 36224646
Drug: 2-channel PCA
Normalized name: CHANNEL CATFISH
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-channel PCA (16 μg/kg of fentanyl, 2 mg/kg of ketorolac, 12 mg of ondansetron)
Study: 36224646
Drug: 1-channel PCA
Normalized name: PCA
DrugBank: Pidolic acid (DB03088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-channel PCA (16 μg/kg of fentanyl, normal saline in continuous channel)
Study: 34590929
Drug: Myo 2
Normalized name: Nymyo 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo 2 g twice daily
Study: 34590929
Drug: Met 850
Normalized name: Glucamet 850 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Met 850 mg twice daily
Study: 33686715
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (listened to the lecture twice)
Study: 36037999
Drug: Digoxin administration
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin administration in patients with heart failure (39 patients, 10.5%)
Study: 36037999
Drug: Digoxin administration
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin administration in patients without heart failure (11 patients, 3.5%)
Study: 35771851
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (singing lessons)
Study: 35972301
Drug: CMO pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CMO pharmaceutical intervention model
Study: 35972301
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (Control Group)
Study: 33851765
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) using Gallium‐aluminum‐arsenide (GaAlAs) diode laser, applied immediately after surgery and for 15 days.
Study: 33851765
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PBMT treatment).
Study: 33518080
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg ALA/bird per day
Study: 33518080
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ALA/bird per day
Study: 33518080
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ALA/bird per day
Study: 33518080
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg ALA/bird per day
Study: 33518080
Drug: 95 mg
Normalized name: aspirin 195 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95 mg ALA/bird per day
Study: 33518080
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg ALA/bird per day
Study: 33518080
Drug: 145 mg
Normalized name: levodopa 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 145 mg ALA/bird per day
Study: 34388977
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of urine and breath samples
Study: 33595409
Drug: All QY
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All QY treatments (250 and 500 ppm)
Study: 32595060
Drug: GLASS Ⅰ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLASS Ⅰ, Ⅱ, and Ⅲ groups (Endovascular treatment)
Study: 32595060
Drug: GLASS Ⅲ
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLASS Ⅲ (Endovascular treatment)
Study: 32595060
Drug: GLASS scoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLASS scoring system (Endovascular treatment)
Study: 32595060
Drug: GLASS score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLASS score groups (Endovascular treatment)
Study: 32595060
Drug: Development group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development group (Endovascular treatment)
Study: 32595060
Drug: Validation sample
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validation sample (Endovascular treatment)
Study: 36274468
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage for 3 days, twice a day, for 15 minutes
Study: 32742507
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic conditioning (twice daily with a maximum of 180 mmHg for 5 days)
Study: 32437332
Drug: ID +
Normalized name: Olly Prenatal Folic Acid + DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID + IL-12 (1.6 mg ID + 0.4 mg pIL-12)
Study: 32437332
Drug: IM +
Normalized name: Jarrow Formulas DIM + CDG Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM + IL-12 (8 mg IM + 1 mg pIL-12)
Study: 32437332
Drug: ID no
Normalized name: red, acid no.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID no IL-12 (1.6 mg ID)
Study: 33439265
Drug: Bimagrumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab (10 mg/kg up to 1200 mg in 5% dextrose solution) every 4 weeks for 48 weeks
Study: 33439265
Drug: Placebo (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5% dextrose solution) every 4 weeks for 48 weeks
Study: 36206262
Drug: Prophylactic acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours
Study: 36206262
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C)
Study: 34554693
Drug: Single-shot thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot thoracic paravertebral block combined with intravenous analgesia (Group P)
Study: 34195628
Drug: 30 tablets
Normalized name: nitrogen 30 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 tablets of hydrocodone (10 mg)–acetaminophen (325 mg)
Study: 34195628
Drug: 60 tablets
Normalized name: Polysorbate 60
DrugBank: Polysorbate 60 (DB14153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 tablets of hydrocodone (10 mg)–acetaminophen (325 mg)
Study: 32580739
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive therapy during pregnancy
Study: 34028494
Drug: Online communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online communication training for clinicians (3 sequential online educational modules and weekly text messages)
Study: 34404983
Drug: Midazolam monotherapy
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam monotherapy
Study: 35801782
Drug: Control care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control care (CC) group
Study: 34255136
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (3 g daily)
Study: 35841235
Drug: mRNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccine (M group; n = 43)
Study: 35841235
Drug: Viral vector
Normalized name: Mx-dnG1 retroviral vector
DrugBank: Rexin G (DB16450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral vector vaccine (V group; n = 42)
Study: 35841235
Drug: mRNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccine (M group)
Study: 35841235
Drug: Viral vector
Normalized name: Mx-dnG1 retroviral vector
DrugBank: Rexin G (DB16450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral vector vaccine (V group)
Study: 34323924
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/d) during chemoradiotherapy and afterward for up to 12 months
Study: 34323924
Drug: Control (platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (platinum-based chemotherapy with concurrent chest radiotherapy)
Study: 38309227
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg 5-HTP daily
Study: 32062860
Drug: Post-operative medication
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative medication checklist
Study: 32062860
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (post-operative pain medication plus VAS form)
Study: 35063244
Drug: Cranberry group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry group (500 mg dry cranberry extract, 2 times daily for 2 months)
Study: 35063244
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (500 mg corn starch, 2 times daily for 2 months)
Study: 34032479
Drug: Single-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose IV administration of MMF (2.5 mg/kg)
Study: 34032479
Drug: Single-dose PO
Normalized name: Zithromax 1g Single-Dose Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose PO administration of MMF (5 mg/kg)
Study: 34032479
Drug: Long-term PO
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term PO administration of MMF (5 mg/kg, PO, q 24 h for 30 days and then 5 mg/kg, PO, q 48 h for an additional 30 days)
Study: 34328481
Drug: SLA surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLA surface implants (Group 1)
Study: 34328481
Drug: Fluorine-modified surface
Normalized name: fluorine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorine-modified surface implants (Group 2)
Study: 34328481
Drug: Anodized surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodized surface implants (Group 3)
Study: 33132344
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g RMD three times daily
Study: 36214230
Drug: Ultrasound-guided trigger
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided trigger point injection (TPI)
Study: 32666079
Drug: Other anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other anti-inflammatory treatments (e.g., methotrexate in Cardiovascular Inflammation Reduction Trial)
Study: 34224601
Drug: Acoustic subcision
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic subcision treatment
Study: 35537314
Drug: Satralizumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satralizumab (120 mg subcutaneous)
Study: 35537314
Drug: Steroid tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid tapering
Study: 34116009
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of IOL rotational stability using nontoric implants in 25 patients with 2 consecutive follow-up visits.
Study: 32654212
Drug: Inotersen 300
Normalized name: INOTERSEN
DrugBank: Inotersen (DB14713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotersen 300 mg weekly for 65 weeks
Study: 35243125
Drug: WATSU (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: WATSU (a passive hands-on treatment in warm water)
Study: 616782981
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia combined with nerve block
Study: 32133503
Drug: Milk (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (600 mL)
Study: 32133503
Drug: Cheese (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheese (100 g)
Study: 32133503
Drug: Soy-based drink
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based drink (600 mL)
Study: 36121672
Drug: Rituximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (500 mg intravenous infusion)
Study: 34314018
Drug: belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: belantamab mafodotin (belamaf) 2.5 mg/kg
Study: 35371086
Drug: Prednisone +
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone + Methotrexate (MTX) 10 mg orally every week
Study: 35469143
Drug: Barley-based remedy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley-based remedy plus conventional medicine
Study: 36379530
Drug: Corticosteroids (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (CS) injections
Study: 35288599
Drug: Dexamethasone 0.25
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.25 mg/kg every 6 hours, 6-12 hours prior to extubation (four doses)
Study: 34074214
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) with 25 daily multi-donor FMT capsules for 12 days
Study: 35869616
Drug: 3-day aspirin
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day aspirin
Study: 35869616
Drug: 0-day aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0-day aspirin + 3-day clopidogrel
Study: 35869616
Drug: 3-day aspirin
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day aspirin + 7-day clopidogrel
Study: 35869616
Drug: 0-day aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0-day aspirin + 7-day clopidogrel
Study: 32295718
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose influenza vaccine (HD) - Sanofi Pasteur Fluzone High Dose [60 mcg × 3 strains]
Study: 32295718
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose influenza vaccine (SD) - Sanofi Pasteur Fluzone® [15 mcg × 3 strains]
Study: 34145518
Drug: Relational Agent
Normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relational Agent + TAU
Study: 32030573
Drug: Nicosulfuron at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicosulfuron at 6 g a.e. ha‐1
Study: 32030573
Drug: Nicosulfuron at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicosulfuron at 12 g a.e. ha‐1
Study: 32030573
Drug: Nicosulfuron at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicosulfuron at 24 g a.e. ha‐1
Study: 32030573
Drug: Nicosulfuron at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicosulfuron at 48 g a.e. ha‐1
Study: 32030573
Drug: Nicosulfuron at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicosulfuron at 60 g a.e. ha‐1
Study: 32030573
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g a.e. ha‐1)
Study: 34787246
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without pre-treatment)
Study: 35933942
Drug: Extended-release injectable
Normalized name: Exenatide for Extended-Release Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release injectable naltrexone (XR-NTX) before release
Study: 35933942
Drug: Extended-release injectable
Normalized name: Exenatide for Extended-Release Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release injectable naltrexone (XR-NTX) referral after release
Study: 34783956
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care together with use of the PROMPT‐QoL
Study: 34783956
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care only
Study: 33277746
Drug: EVL/MPA/steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVL/MPA/steroids
Study: 34627499
Drug: Antimicrobial stewardship
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial stewardship intervention (education, engaging opinion leaders, prospective audit and feedback of antibiotic use)
Study: 34627499
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (broad-spectrum antibiotics)
Study: 34627499
Drug: Intervention period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention period (antibiotic stewardship)
Study: 35555211
Drug: Mid-Luteal (ML)
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-Luteal (ML) phase
Study: 36481522
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate and nicardipine (combination therapy)
Study: 34034418
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg/day